B7-33 vs Serrapeptase
A side-by-side research comparison of B7-33 and Serrapeptase across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | Serrapeptase |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Serrapeptase (Serratiopeptidase) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | Dietary supplement |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | Degrades non-living tissue including fibrin, blood clots, mucus, and arterial plaque without harming living cells. Inhibits bradykinin release and reduces prostaglandin synthesis for anti-inflammatory effects. |
| Molecular weight | ~3.3 kDa | ~52,000 Da |
| Half-life | Short (peptide) | ~4-6 hours |
| Bioavailability | Injection (research) | Oral (enteric-coated required); detectable in bloodstream |
| Typical dose | Not established for humans | 120,000-240,000 SPU |
| Frequency | Research only | Daily on empty stomach |
| Route | Injection (research) | Oral (enteric-coated) |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Serrapeptase reported benefits
- Reduced inflammation and swelling
- Arterial plaque modulation
- Mucus/biofilm breakdown
- Post-surgical recovery
- Sinus/respiratory clearing
- Pain reduction
Related comparisons
Research and educational reference only. Not medical advice.